Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer Inc.    PFE


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Pfizer Could Apply for Emergency Use of Covid-19 Vaccine by Late November

share with twitter share with LinkedIn share with facebook
10/16/2020 | 06:24am EDT

By Bojan Pancevski

Pfizer Inc. said it could be ready to apply for emergency-use authorization of its Covid-19 vaccine by late November, assuming it receives positive efficacy and safety data from late-stage human trials now under way.

The drug giant, which is developing its vaccine candidate with German partner BioNTech SE, said it continues to expect to have data on the vaccine's effectiveness -- whether it protects at least a majority of vaccinated people from the disease -- later this month. It then expects to have data on the drug's safety by the third week of November.

Assuming positive results with both sets of data, Pfizer said it then plans to file for emergency-use authorization for the vaccine in the U.S. from the Food and Drug Administration soon after receiving the safety data. It didn't disclose timing for similar applications anywhere else in the world.

A third set of data -- to ensure the drug can be manufactured on a large scale at the right quality and consistency -- will be ready for submission before Pfizer expects to receive the safety data.

Pfizer said it laid out the timeline in an effort to clear up any confusion about the complex process. "To ensure public trust and clear up a great deal of confusion, I believe it is essential for the public to understand our estimated timelines," Pfizer Chief Executive Albert Bourla said in an open letter released early Friday.

Write to Bojan Pancevski at bojan.pancevski@wsj.com

(END) Dow Jones Newswires

10-16-20 0623ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 0.72% 94.585 Delayed Quote.177.21%
PFIZER INC. -0.54% 37.595 Delayed Quote.-3.14%
PFIZER LIMITED 0.10% 4997.55 End-of-day quote.18.31%
share with twitter share with LinkedIn share with facebook
All news about PFIZER INC.
02:44pEXCLUSIVE : AstraZeneca U.S. COVID-19 vaccine trial may resume as soon as this w..
01:50pMexico will pay for any COVID-19 vaccine liabilities, government says
05:06aPFIZER : Covid-19 - Another Vaccine Proposed
10/19Moderna CEO Expects Covid-19 Vaccine Interim Results in November
10/19Moderna CEO Expects Covid-19 Vaccine Interim Results in November
10/19Global equities decline on COVID lockdown fears
10/19Dollar eases on cautious optimism around U.S. fiscal package
10/19LabCorp launches test to measure COVID-19 antibodies in clinical trials
10/19South Africa's rand firms on improved risk appetite
10/19Asian markets jump on vaccine, U.S. aid hopes; China data caps gains
More news
Financials (USD)
Sales 2020 49 137 M - -
Net income 2020 13 097 M - -
Net Debt 2020 38 391 M - -
P/E ratio 2020 17,9x
Yield 2020 4,01%
Capitalization 210 B 210 B -
EV / Sales 2020 5,06x
EV / Sales 2021 4,24x
Nbr of Employees 88 300
Free-Float 59,1%
Duration : Period :
Pfizer Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 42,16 $
Last Close Price 37,80 $
Spread / Highest target 45,5%
Spread / Average Target 11,5%
Spread / Lowest Target -7,41%
EPS Revisions
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Wyllie Don Cornwell Independent Director
Suzanne Nora Johnson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC.-3.14%210 050
JOHNSON & JOHNSON-1.06%379 969
ROCHE HOLDING AG-0.81%292 399
MERCK & CO., INC.-13.50%198 975
NOVARTIS AG-14.48%190 349
NOVO NORDISK A/S16.68%166 008